THERAPIE PAR EPUISEMENT DE KLRG1

• 收藏
• 分享

专利权人:

INC.;THE BRIGHAM AND WOMEN'S HOSPITAL, INC.;CHILDREN'S MEDICAL CENTER CORPORATION;THE BRIGHAM AND WOMENS HOSPITAL

发明人:

GREENBERG, STEVEN,GULLA, STEFANO VINCENZO,THOMPSON, KENNETH EVAN

申请号：

CA3036835

公开号：

CA3036835A1

申请日:

2017.09.15

申请国别(地区):

CA

年份:

2018

代理人:

摘要：

A method of treating a subject can comprise administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent, thereby depleting CD8+ cytotoxic T and/or NK cells in vivo. A method of treating a subject can comprise administering to a subject in need thereof an effective amount of a KLRG1 depleting agent with effector killing function. A composition, for example an anti-KLRG1 antibody, can comprise a KLRG1 depleting agent. The methods and compositions can be used for various diseases in which KLRG1 is overexpressed, for example autoimmune diseases, transplant rejection, hematologic malignancies, and solid tumors.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/